Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 113

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 113
---
 Agreement. Under the employment agreement, upon the Closing of the Merger, Mr.Twito shall also be entitled to a bonus equal to the NIS equivalent of $100,000; •Mr.Kfir Molakandov’s, Kadimastem’s VP of Research and Development, annual salary will increase to a NIS amount (according to the NIS to USD rate as of August28, 2025) equivalent to $187,669, including social benefits; •Mr.Ariel Revel’s, Director of Medical Affairs of Kadimastem, annual salary will increase to a NIS amount (according to the NIS to USD rate as of August28, 2025) equivalent to $93,835, including social benefits; and •Each director on the NLS Board (1) shall receive an annual amount of $25,000, payable quarterly, and a one -timeoption grant equal to 0.2% of the outstanding NLS Common Shares, with the initial vesting over three (3) years, with an exercise price equal to the market price at the Closing; and (2) will enter into indemnification agreements between NLS and members of the board of directors. Additionally, Prof. Michel Revel, MD, Director and Chief Scientific Officer of Kadimastem and the beneficial owner of 1,313,877 Kadimastem Ordinary Shares as of August 28, 2025, and Ronen Twito, Executive Chairman and CEO of Kadimastem, and beneficial owner of 367,332 Kadimastem Ordinary shares as of August 28, 2025, will benefit directly from the exchange of their Kadimastem Ordinary Shares in exchange for NLS Common Shares resulting from the Merger. Treatment of Kadimastem and Kadimastem’s Equity Awards and Award Plan (Page 145) At the Effective Time each option, restricted share unit, restricted share, warrant or other rights issued and outstanding, whether vested or unvested, to purchase Kadimastem Ordinary Shares, shall be assumed by NLS and converted into an option, warrant, other award, or right, as applicable, to purchase NLS Common Shares in accordance with the terms of the Merger Agreement. For more information please see “ The Merger Agreement — Equity Awards and Warrants” of this proxy statement/prospectus. No Solicitation of Acquisition Proposals (Page 147) NLS also agreed during the period between the signing of the Merger Agreement and